BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32365240)

  • 1. Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma.
    Jeon MY; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Han KH; Ahn SH; Kim SU
    J Viral Hepat; 2020 Sep; 27(9):932-940. PubMed ID: 32365240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
    Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis.
    Huang ZH; Lu GY; Qiu LX; Zhong GH; Huang Y; Yao XM; Liu XH; Huang SJ; Wu T; Yuan Q; Wang YB; Su YY; Zhang J; Xia NS
    BMC Cancer; 2022 Mar; 22(1):287. PubMed ID: 35300634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment.
    Wong GL; Chan HL; Tse YK; Yip TC; Lam KL; Lui GC; Szeto CC; Wong VW
    Aliment Pharmacol Ther; 2018 Nov; 48(9):984-992. PubMed ID: 30125952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
    Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients.
    Lee J; Park JY; Yang SJ; Lee JY; Kim DG; Joo DJ; Kim MS; Kim SI; Lee JG
    J Viral Hepat; 2020 Aug; 27(8):818-825. PubMed ID: 32302037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.
    Choi J; Jo C; Lim YS
    Hepatology; 2021 Feb; 73(2):661-673. PubMed ID: 32324905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients.
    Tsai HJ; Chuang YW; Lee SW; Wu CY; Yeh HZ; Lee TY
    Aliment Pharmacol Ther; 2018 Jun; 47(12):1673-1681. PubMed ID: 29696665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection.
    Wang XH; Hu ZL; Fu YZ; Hou JY; Li WX; Zhang YJ; Xu L; Zhou QF; Chen MS; Zhou ZG
    J Gastroenterol; 2022 Mar; 57(3):185-198. PubMed ID: 35152312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
    Yip TC; Wong VW; Chan HL; Tse YK; Lui GC; Wong GL
    Gastroenterology; 2020 Jan; 158(1):215-225.e6. PubMed ID: 31574268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
    Rodríguez-Nóvoa S; García-Samaniego J; Prieto M; Calleja JL; Pascasio JM; Delgado Blanco M; Crespo J; Buti M; Bonet Vidal ML; Arenas Ruiz Tapiador J; Fernández-Rodríguez C; Solá R; Fraga E; González Diéguez L; Núñez O; Praga M; Del Pino-Montes J; Romero-Gómez M; Morillas R; Diago M; Castro Á;
    J Clin Gastroenterol; 2016 Oct; 50(9):779-89. PubMed ID: 27332746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
    Choi H; Seo GH
    J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of renal events during tenofovir disoproxil fumarate and entecavir antiviral prophylaxis in HBsAg-positive cancer patients undergoing chemotherapy.
    Lee IC; Chao Y; Li CP; Su CW; Lan KH; Lin HC; Hou MC; Huang YH
    J Viral Hepat; 2018 Dec; 25(12):1599-1607. PubMed ID: 30125436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Su F; Berry K; Ioannou GN
    Gut; 2021 Feb; 70(2):370-378. PubMed ID: 32229544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma.
    Lee JH; Kim BK; Park SY; Tak WY; Park JY; Kim DY; Ahn SH; Sinn DH; Kim SU
    Eur J Intern Med; 2021 Jul; 89():48-55. PubMed ID: 33810942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.
    Lampertico P; Berg T; Buti M; Pathil A; Petersen J; Ryder SD; Zoulim F; Botros I; Flaherty JF; Jump B; Op den Brouw ML; van Troostenburg A; Ramroth H;
    Aliment Pharmacol Ther; 2020 Aug; 52(3):500-512. PubMed ID: 32583915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Entecavir and Tenofovir on Renal Function in Patients with Hepatitis B Virus-Related Compensated and Decompensated Cirrhosis.
    Park J; Jung KS; Lee HW; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
    Gut Liver; 2017 Nov; 11(6):828-834. PubMed ID: 28651305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.